Effect of High/Low Dose N-Acetylcysteine on Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

References

• Hillas G, Nikolakopoulou S, Hussain S, Vassilakopoulos T. Antioxidants and mucolytics in COPD management: When (if ever) and in whom? Curr Drug Targ 2013; 14(2):225–234.
   PubMed Web of Science ®Google Scholar
• Pinho RA, Chiesa D, Mezzomo KM, Andrades ME, Bonatto F, Gelain D, Oxidative stress in chronic obstructive pulmonary disease patients submitted to a rehabilitation program. Respir Med 2007; 101(8):1830–1835.
   PubMed Web of Science ®Google Scholar
• Ochs-Balcom HM, Grant BJ, Muti P, Sempos CT, Freudenheim JL, Browne RW, Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma or COPD. Euro J Clin Nutr 2006; 60(8):991–999.
   PubMed Web of Science ®Google Scholar
• Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167(8):1090–1095.
   PubMed Web of Science ®Google Scholar
• Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des, Develop Ther 2012; 6:261–272.
   PubMed Web of Science ®Google Scholar
• Dauletbaev N, Fischer P, Aulbach B, Gross J, Kusche W, Thyroff-Friesinger U, A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Euro J Med Res 2009; 14(8):352–358.
   PubMed Web of Science ®Google Scholar
• Pela R, Calcagni AM, Subiaco S, Isidori P, Tubaldi A, Sanguinetti CM. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respir Inter Rev Thor Dis 1999; 66(6):495–500.
   Google Scholar
• Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88(7):531–535.
   PubMed Web of Science ®Google Scholar
• Tse HN, Raiteri L, Wong KY, Yee KS, Ng LY, Wai KY, High-Dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-Year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144(1):106–118.
   PubMed Web of Science ®Google Scholar
• Schermer T, Chavannes N, Dekhuijzen R, Wouters E, Muris J, Akkermans R, Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir Med 2009; 103(4):542–551.
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005; 365(9470):1552–1560.
   PubMed Web of Science ®Google Scholar
• Stolarek R, Bialasiewicz P, Nowak D. N-acetylcysteine effect on the luminol-dependent chemiluminescence pattern of reactive oxygen species generation by human polymorphonuclear leukocytes. Pulmon Pharmacol Therap 2002; 15(4):385–392.
   PubMed Web of Science ®Google Scholar
• Benrahmoune M, Therond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Rad Biol Med 2000; 29(8):775–782.
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD 2006; 3(4):195–202.
   PubMedGoogle Scholar
• Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Euro Respir J Off J Euro Soc Clin Respir Physiol 2000; 16(2):253–262.
   PubMed Web of Science ®Google Scholar
• Sadowska AM, Manuel YKB, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulmon Pharmacol Ther 2007; 20(1):9–22.
   PubMed Web of Science ®Google Scholar
• Boman G, Backer U, Larsson S. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Euro J Respir Dis 1983; 64(6):405–415.
   PubMedGoogle Scholar
• Multicenter Study Group. Long-term oral acetylcysteine in chronic bronchitis.a double-blind controlled study. Euro J Respir Dis Suppl. 1980; 111:93–108.
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, Assessing the quality of reports of randomized clinical trials: is blinding necessary? Contr Clin Trials 1996; 17(1):1–12.
   PubMedGoogle Scholar
• Bachh AA, Shah NN, Bhargava R, Ahmed Z, Pandey DK, Dar KA, Effect of oral N-acetylcysteine in COPD—A randomised controlled trial. JK Practitioner 2007; 14(1):12–16.
   Google Scholar
• Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Euro Respir J 1988; 1(4):351–355.
   PubMed Web of Science ®Google Scholar
• McGavin CR, Prescott RJ, Nariman S, Macfarlane JT. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40(11):832–835.
   PubMed Web of Science ®Google Scholar
• Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Euro J Clin Pharmacol 1976; 9(5–6):393–396.
   Web of Science ®Google Scholar
• Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Therap 2000; 22(2):209–221.
   PubMed Web of Science ®Google Scholar
• Patil AB, Kale AB, Singhal SS, Khan TA. Study of malondialdehyde as an indicator of oxidative stress and its modulation by N-acetylcysteine in chronic obstructive pulmonary disease. J Clin Diag Res 2011; 5(1):48–51.
   Google Scholar
• Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009; 136(2):381–6. Epub 2009/05/19. doi: 10.1378/chest.09-0421. PubMed PMID: 19447919.
   PubMed Web of Science ®Google Scholar
• Van Overveld FJ, Demkow UA, Gorecka D, Bialas-Chromiec B, Sadowska AM, Goljan A, The effects of N-acetylcysteine and inhaled steroid on inflammatory and oxidative stress markers in chronic obstructive pulmonary disease (COPD). Central-European Journal of Immunology. 2008; 33(3):135–41.
   Web of Science ®Google Scholar
• Sadowska AM, van Overveld FJ, Gorecka D, Zdral A, Filewska M, Demkow UA, The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respiratory medicine. 2005; 99(2):241–9. Epub 2005/02/18. PubMed PMID: 15715193.
   Google Scholar
• Dorow P, Weiss T, Felix R, Kohler M. Influence of tasuldine and acetylcysteine on mucociliary clearance in patients with chronic airways obstruction. Arzneimittel-Forschung. 1986; 36(1):131–3. Epub 1986/01/01. PubMed PMID: 3954815.
   PubMed Web of Science ®Google Scholar
• Patil AB, Kale AB, Singhal SS, Khan TA. Study of malondialdehyde as an indicator of oxidative stress and its modulation by N-acetylcysteine in chronic obstructive pulmonary disease. Journal of Clinical and Diagnostic Research. 2011; 5(1):48–51.
   Google Scholar
• Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clinical drug investigation. 2005; 25(6):401–8. Epub 2007/05/30. PubMed PMID: 17532680.
   Google Scholar
• Barbaro MPF, Serviddio G, Resta O, Rollo T, Tamborra R, Carpagnano GE, Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: Prevention by N-acetyl cysteine. Free Radical Research. 2005; 39(10):1111–8.
   PubMed Web of Science ®Google Scholar
• De Benedetto F, Aceto A, Dragani B, Spacone A, Formisano S, Pela R, Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulmonary Pharmacology and Therapeutics. 2005; 18(1):41–7.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study. Copd. 2013; 10(2):164–71. Epub 2012/10/16. doi: 10.3109/15412555.2012.732628. PubMed PMID: 23061828.
   PubMedGoogle Scholar
• Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC pulmonary medicine. 2004; 4:13. Epub 2004/12/08. doi: 10.1186/1471-2466-4-13. PubMed PMID: 15581425; PubMed Central PMCID: PMC539269.
   PubMedGoogle Scholar
• van Overveld FJ, Demkow U, Gorecka D, de Backer WA, Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2005; 56 Suppl 4:135–42. Epub 2005/10/06. PubMed PMID: 16204787.
   Google Scholar